Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

被引：20

作者：

Uckun, Fatih M. ^{[1
,2
]}

Qazi, Sanjive ^{[3
]}

机构：

[1] Childrens Hosp Los Angeles, Dev Therapeut Program, Inst Pediat Clin Res, Los Angeles, CA 90027 USA

[2] Univ So Calif, Dept Pediat, Div Hematol Oncol, Sch Med,Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA

[3] Gustavus Adolphus Coll, St Peter, MN 56082 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 09期

关键词：

leukemia; lymphoma; nanotechnology; rational drug design; RNA interference; spleen tyrosine kinase; tyrosine kinase inhibitor; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL ANTIGEN RECEPTOR; CHILDRENS-ONCOLOGY-GROUP; PRIMARY CLONOGENIC BLASTS; NON-HODGKIN-LYMPHOMA; BONE-MARROW RELAPSE; B-CELLS; PHOSPHOINOSITIDE; 3-KINASE; APOPTOTIC RESISTANCE; THERAPEUTIC TARGET;

D O I：

10.1586/ERA.10.112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Spleen tyrosine kinase (SYK) has emerged as a potential molecular target for the treatment of B-lineage leukemias and lymphomas. Here, we provide an overview of the current state of knowledge regarding the regulatory signaling function of SYK and its role in the pathogenesis of B-lineage lymphoid malignancies, available methods and drug candidates for targeting SYK, as well as compelling preclinical and clinical evidence regarding the clinical potential of inhibiting SYK. The further development of rationally designed SYK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias and lymphomas.

引用

页码：1407 / 1418

页数：12

共 50 条

[31] Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? [J].

Lorenzo-Vizcaya, Ana ;

Fasano, Serena ;

Isenberg, David A. .

IMMUNOTARGETS AND THERAPY, 2020, 9 :105-110

[32] Is spleen tyrosine kinase inhibition an effective therapy for patients with RA? [J].

Hueber, Axel J. ;

McInnes, Iain B. .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (03) :130-131

[33] Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia [J].

Feng, Gege ;

Wang, Xin .

LEUKEMIA & LYMPHOMA, 2014, 55 (12) :2699-2705

[34] Effect of spleen tyrosine kinase on nonsmall cell lung cancer [J].

Hao, Ying Tao ;

Peng, Chuan Liang ;

Zhao, Yun Peng ;

Sun, Qi Feng ;

Zhao, Xiao Gang ;

Cong, Bo .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 :S100-S104

[35] Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors [J].

Huang, Yahui ;

Li, Yu ;

Dong, Guoqiang ;

Zhang, Wannian ;

Liu, Na ;

Sheng, Chunquan .

ARCHIV DER PHARMAZIE, 2018, 351 (08)

[36] Spleen tyrosine kinase (SYK) inhibitor Hematological cancer therapy [J].

Wei, Zeng-Hui ;

Koya, Jagadish ;

Dong, Xing-Duo ;

Reznik, Sandra E. ;

Chen, Zhe-Sheng .

DRUGS OF THE FUTURE, 2022, 47 (02) :99-107

[37] Prognostic value of spleen tyrosine kinase in human solid tumors [J].

Ni, Beibei ;

Li, Shi ;

Liu, Yang ;

Huang, Yuqian ;

Li, Zesong .

ONCOTARGETS AND THERAPY, 2018, 11 :3377-3384

[38] MENINGEAL INVOLVEMENT IN LEUKEMIAS AND MALIGNANT-LYMPHOMAS OF ADULTS - INCIDENCE, COURSE OF DISEASE, AND TREATMENT FOR PREVENTION [J].

WEIZSAECKER, M ;

KOELMEL, HW .

ACTA NEUROLOGICA SCANDINAVICA, 1979, 60 (06) :363-370

[39] SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias [J].

Bourrie, Bernard ;

Brassard, Diana L. ;

Cosnier-Pucheu, Sylvie ;

Zilberstein, Asher ;

Yu, Kin ;

Levit, Mikhail ;

Morrison, J. Gil ;

Perreaut, Pierre ;

Jegham, Samir ;

Hilairet, Sandrine ;

Bouaboula, Monsif ;

Penarier, Geraldine ;

Guiot, Cecile ;

Larroze-Chicot, Philippe ;

Laurent, Guy ;

Demur, Cecile ;

Casellas, Pierre .

LEUKEMIA & LYMPHOMA, 2013, 54 (07) :1488-1499

[40] Suppression of Skin and Kidney Disease by Inhibition of Spleen Tyrosine Kinase in Lupus-Prone Mice [J].

Deng, Guo-Min ;

Liu, Lena ;

Bahjat, Frances Rena ;

Pine, Polly R. ;

Tsokos, George C. .

ARTHRITIS AND RHEUMATISM, 2010, 62 (07) :2086-2092

← 1 2 3 4 5 →